The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors
Titel:
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors
Auteur:
Yamamoto, N. Murakami, H. Nishina, T. Hirashima, T. Sugio, K. Muro, K. Takahashi, T. Naito, T. Yasui, H. Akinaga, S. Koh, Y. Boku, N.